Marvin & Palmer Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$9.52M |
| 2 |
Merck
MRK
|
+$9.39M |
| 3 |
Linde
LIN
|
+$9.29M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$8.04M |
| 5 |
KLA
KLAC
|
+$7.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ameriprise Financial
AMP
|
+$11.8M |
| 2 |
VanEck Agribusiness ETF
MOO
|
+$10.5M |
| 3 |
Tractor Supply
TSCO
|
+$7.96M |
| 4 |
SCHW
Charles Schwab
SCHW
|
+$7.8M |
| 5 |
iShares Core US REIT ETF
USRT
|
+$7.61M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.75% |
| 2 | Financials | 16.71% |
| 3 | Technology | 15.69% |
| 4 | Energy | 13.06% |
| 5 | Industrials | 8.65% |
Similar funds
Marvin & Palmer Associates's Q2 2022 Portfolio in Review
As of Q2 2022, Marvin & Palmer Associates held 35 positions worth $194M, down 12% from $222M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Marvin & Palmer Associates withdrew a net $9.43M in Q2 2022, closing 8 positions and reducing 10 holdings. Its most notable exit was Ameriprise Financial, an estimated $11.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marvin & Palmer Associates opened a new position in Eli Lilly worth $10.3M.
- Marvin & Palmer Associates's largest Q2 2022 buy was Eli Lilly: 31,700 shares worth $10.3M.
- Marvin & Palmer Associates's biggest Q2 2022 reduction was Fortinet, cutting an estimated $1.95M.
- Marvin & Palmer Associates fully exited Ameriprise Financial in Q2 2022, selling an estimated $11.8M.
- Marvin & Palmer Associates's ten largest holdings make up 50% of its $194M portfolio in Q2 2022.
- Marvin & Palmer Associates opened 6 new positions and closed 8 in Q2 2022.
- Marvin & Palmer Associates's portfolio value fell 12% quarter-over-quarter to $194M.
Based on Marvin & Palmer Associates's 13F filing for Q2 2022, filed 9 Aug 2022.